| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2002 | WO2001029055A3 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| 02/14/2002 | WO2001025489A3 Diagnostic and therapeutic uses for a gene differentially expressed in prostate cancer |
| 02/14/2002 | WO2001021771A3 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 02/14/2002 | WO2001014418A3 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 02/14/2002 | WO2001012169A3 Method of cancer treatment |
| 02/14/2002 | WO2000067698A3 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation |
| 02/14/2002 | WO2000066101A3 Method of inhibiting glycation product formation |
| 02/14/2002 | WO2000064431A9 Pharmaceutical compositions of tetrac and methods of use thereof |
| 02/14/2002 | WO2000061188A9 Sodium channel blocker compositions and the use thereof |
| 02/14/2002 | WO2000059469A9 Endodontic fibers and methods of use therefor |
| 02/14/2002 | WO2000050023A9 Use of tamoxifen and related compounds as clc3 blockers in the treatment of vascular diseases |
| 02/14/2002 | WO2000043395A8 Substituted porphyrins |
| 02/14/2002 | WO1995029669A3 Multifunctional ligand for use as a diagnostic or therapeutic pharmaceutical |
| 02/14/2002 | WO1995001170A3 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders |
| 02/14/2002 | US20020019991 Compositions containing an alpha 1,2-fucose linkage and uses thereof |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019547 Skin disorders; reacting retinol with chloroformate compound |
| 02/14/2002 | US20020019544 Bioavailability |
| 02/14/2002 | US20020019540 Conformationally constrained compounds as pharmaceutical agents |
| 02/14/2002 | US20020019538 Prevention binding of transcription factor tozinc finger binding compounds |
| 02/14/2002 | US20020019537 Novel processes for preparing torsemide intermediate |
| 02/14/2002 | US20020019534 Gem substituted hydroxamic acids |
| 02/14/2002 | US20020019533 Piperidine derivatives and anti-platelet agents containing the same |
| 02/14/2002 | US20020019531 Indoles |
| 02/14/2002 | US20020019530 Antitumor agent |
| 02/14/2002 | US20020019526 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/14/2002 | US20020019525 Pyrido [2,3-b] indolizine derivatives and aza analogues thereof; CRF1 specific ligands |
| 02/14/2002 | US20020019524 Chemical synthesis of morpholine derivatives |
| 02/14/2002 | US20020019523 Dietetics; antidabetic agents; sexual disrders |
| 02/14/2002 | US20020019522 Steroids |
| 02/14/2002 | US20020019515 Novel spoIIIE |
| 02/14/2002 | US20020019445 Topical applying |
| 02/14/2002 | US20020019444 Anandamide and structurally related lipids as vanilloid receptor modulators |
| 02/14/2002 | US20020019443 Therapeutic use of D-methionine to reduce the toxicity of noise |
| 02/14/2002 | US20020019439 Therapeutic quassinoid preparations with antineoplastic, antiviral, and herbistatic activity |
| 02/14/2002 | US20020019438 Respiratory system disorders |
| 02/14/2002 | US20020019437 Aids therapy |
| 02/14/2002 | US20020019434 Indole derivatives having an antiviral activity |
| 02/14/2002 | US20020019433 Methods of treating excessive intraocular pressure |
| 02/14/2002 | US20020019432 Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds |
| 02/14/2002 | US20020019431 Porous celecoxib matrices and methods of manufacture thereof |
| 02/14/2002 | US20020019426 Therapy for amyotropic lateral sclerosis |
| 02/14/2002 | US20020019425 Anticancer agents; administering p53 gene or protein |
| 02/14/2002 | US20020019424 1-sulfonyl pyrrolidine derivatives |
| 02/14/2002 | US20020019423 Anti-viral triaza compounds |
| 02/14/2002 | US20020019421 Compositions and therapy for substance addiction |
| 02/14/2002 | US20020019420 Antiulcer agents; side effect reduction |
| 02/14/2002 | US20020019418 Methods of preventing breast cancer |
| 02/14/2002 | US20020019417 Methods, compounds and compositions for treating gout |
| 02/14/2002 | US20020019416 Esters and amides as pla2 inhibitors |
| 02/14/2002 | US20020019415 Cancer treatment |
| 02/14/2002 | US20020019414 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors |
| 02/14/2002 | US20020019413 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents |
| 02/14/2002 | US20020019411 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 02/14/2002 | US20020019409 Treating allergic and inflammatory conditions |
| 02/14/2002 | US20020019407 Methylxanthines in the diagnosis and treatment of autistic disorder |
| 02/14/2002 | US20020019406 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands |
| 02/14/2002 | US20020019405 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| 02/14/2002 | US20020019404 Anticancer agents, skin disorders |
| 02/14/2002 | US20020019403 Inhibit amyloid protein deposits |
| 02/14/2002 | US20020019402 Integrin inhibitors and their methods of use |
| 02/14/2002 | US20020019401 Psychological disorders; adjustment of dopamine concentration |
| 02/14/2002 | US20020019398 Methods of making and using N-desmethylzopiclone |
| 02/14/2002 | US20020019397 Heterocycle carboxamides as antiviral agents |
| 02/14/2002 | US20020019396 Pharmaceutically active morpholinol |
| 02/14/2002 | US20020019393 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain |
| 02/14/2002 | US20020019392 By administering indole compounds such as 1-(4-(2-Azepan-1yl-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5 -ol; epilepsy, asthma, eating disorders, obesity, neurodegenertive conditions, schizophrenia |
| 02/14/2002 | US20020019391 Combinations of statins and estrogenic agents |
| 02/14/2002 | US20020019390 Imidazole and imidazoline derivatives and uses thereof |
| 02/14/2002 | US20020019386 5-HT4 receptor antagonists |
| 02/14/2002 | US20020019385 Activator protein (AP); treating diseases associated with immune suppressive states; benzmides such as N-((2-Diethylamino)propyl)-4-isobutyrylamino-2-methoxy-benzamide |
| 02/14/2002 | US20020019382 Curcumin analogs with anti-tumor and anti-angiogenic properties |
| 02/14/2002 | US20020019381 In fewer steps and is obtained in higher yield; chemical intermediates; useful in treating methicillin resistent Staphylococcus aureus and Pseudomonas aeruginosa |
| 02/14/2002 | US20020019380 1-(6-((dimethylamino)methyl)-1-methyl-2,3,5,6-tetrahydro-1H -cyclobuta(f)indol-6-yl)cyclohexanol, for example; treating psychological disorders such as depression, panic attacks, phobias, drug abuse, as well as obesity and bulemia |
| 02/14/2002 | US20020019379 Pregnan-3-ol-20-ones |
| 02/14/2002 | US20020019376 Steroid derived antibiotics |
| 02/14/2002 | US20020019375 Method of inhibiting angiogenesis using active vitamin D analogues |
| 02/14/2002 | US20020019373 Treating bone disease in mammals by administering 1-(4-(2-Azepan-1yl-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5 -ol and a bisphonate such as alendronate sodium |
| 02/14/2002 | US20020019372 New medical use; ophthalmic composition, treating nephrotoxicity, ischemia- and drug-induced acute renal failure, and glomerulonephritis, and skin abrasions, cuts, and burns |
| 02/14/2002 | US20020019368 Decyclization with an alkali metal or quaternary ammonium borohydride; antiinflammatory agents |
| 02/14/2002 | US20020019367 Compositions and methods for modulation of vascular structure and/or function |
| 02/14/2002 | US20020019366 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives |
| 02/14/2002 | US20020019365 Encapsulation is dissolution resistant at a pH of about 4 to 5 or less and dissolves at a pH of greater than about 4 to 5 |
| 02/14/2002 | US20020019364 Compounds for the treatment of psychiatric or substance abuse disorders |
| 02/14/2002 | US20020019363 Viricides for hepatitis c |
| 02/14/2002 | US20020019361 Persistent transgene expression, repeated administration of the therapy |
| 02/14/2002 | US20020019360 Treatment for cardiovascular disease |
| 02/14/2002 | US20020019357 Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 02/14/2002 | US20020019355 Oxacyclotetradecane derivatives against methicillin resistant strains of staphylococcus |
| 02/14/2002 | US20020019354 Method of treatment of seborrheic dermatitis |
| 02/14/2002 | US20020019353 Single-dose administration |
| 02/14/2002 | US20020019351 Treatment of skeletal disorders |
| 02/14/2002 | US20020019345 Administering to a patient having implant an effective amount of antagonist of CCR5 (chemokine receptor 5) function, to inhibit graft rejection, antagonist selected from small organic molecules, peptides, proteins, peptidomimetics |
| 02/14/2002 | US20020019344 Treating or ameliorating the post-transplantation syndrome complex associated with allograft rejection and immunosuppressive pharmacotherapy used to prevent allograft rejection |
| 02/14/2002 | US20020019340 Polymer stabilized neuropeptides |
| 02/14/2002 | US20020019334 Nutritional intervention composition for enhancing and extending satiety |
| 02/14/2002 | US20020019332 Method of inducing apoptosis in b-lymphocytes |
| 02/14/2002 | US20020019000 Polynucleotides coexpressed with matrix-remodeling genes |
| 02/14/2002 | US20020018821 Process for the purification of a red fruit extract containing anthocyanosides, extract obtained from the process and use of said extract |
| 02/14/2002 | US20020018819 Heating, pulverization; cyclodextrin solubilizers |